Date: 2014-06-30
Type of information: Collaboration agreement
Compound: microRNA signatures
Company: TTFactor (Italy) Gensignia (UK)
Therapeutic area: Diagnostic - Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism:
Disease: lung cancer, breast cancer, ovarian cancer and other cancers
Details: *On June 30, 2014, Gensignia has entered into a collaboration agreement with TTFactor, acting on behalf of the FIRC (the Italian Foundation for Cancer Research) Institute for Molecular Oncology (IFOM) and the European Institute of Oncology (IEO). The collaboration is focused on developing microRNA-based signatures for the early detection of tumors in lung, breast, ovarian and other cancers. The research to detect early stage lung cancer was originated by IFOM, IEO and university of Milan research. It is currently being validated on a large cohort of patients in the COSMOS II clinical study sponsored by IEO.
Financial terms:
Latest news:
